HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCEPRNewsWire • 02/17/26
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum StockZacks Investment Research • 02/16/26
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 02/13/26
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating ResultsPRNewsWire • 02/10/26
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 02/10/26
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-TermZacks Investment Research • 02/04/26
5 Stocks To Watch Trade Near Buy Points; Three Are Data Center PlaysInvestors Business Daily • 01/31/26
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-TermZacks Investment Research • 01/30/26
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 GuidanceZacks Investment Research • 01/29/26
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial GuidancePRNewsWire • 01/28/26
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business UpdatePRNewsWire • 01/20/26
Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 01/13/26
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®PRNewsWire • 01/08/26
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for ObesityPRNewsWire • 01/05/26
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung CancerPRNewsWire • 12/18/25
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-TermZacks Investment Research • 12/09/25